Sensei Biotherapeutics (SNSE) just unveiled an update.
Sensei Biotherapeutics, Inc. has engaged its former CFO, Erin Colgan, in a consulting role to aid with company transition services until April 30, 2024. Colgan will receive a daily fee of $1,640 for her expertise. Furthermore, her vested stock options have been extended, offering her the flexibility to exercise them until October 7, 2024, or as per the terms of the equity plan and option award agreement. This strategic move ensures the company benefits from Colgan’s financial acumen during the transition period.
See more data about SNSE stock on TipRanks’ Stock Analysis page.
